Cancer Archives

News and Trends 19 Dec 2022

Sanofi and Innate Pharma expand natural killer cell deal

Sanofi and Innate Pharma SA have expanded their collaboration, with Sanofi licensing a natural killer (NK) cell engager program targeting B7H3 from Innate’s ANKET (Antibody-based NK Cell Engager Therapeutics) platform. Sanofi will also have the option to add up to two additional ANKET targets. Upon candidate selection, Sanofi will be responsible for all development, manufacturing and […]

December 19, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 19 Dec 2022

LIfT BioSciences gets a double boost

LIfT BioSciences’ is receiving more investment, and has been accepted into Johnson & Johnson Innovation’s JLABS network. LIfT BioSciences’ lead investor, Starbloom Capital, provided further investment into the company to accelerate LIfT’s R&D plans and progress N-LIfT, the company’s first-to-market anti-cancer innate cell therapy, (neutrophil only leukocyte infusion therapy) into clinical development by Q1 2024, […]

December 19, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 19 Dec 2022

Nykode Therapeutics and Richter-Helm BioLogics announce partnership

Nykode Therapeutics ASA has entered into a strategic manufacturing partnership with Richter-Helm BioLogics GmbH & Co KG to supply plasmid DNA for Nykode’s wholly owned and partnered product portfolio. “We are excited about the strategic manufacturing partnership with Richter-Helm BioLogics. As a leading manufacturer of DNA vaccines, they will provide the long-term expertise and capacity […]

December 19, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 16 Dec 2022

Astellas gastric cancer drug meets phase 3 primary endpoint

Astellas Pharma Inc. has announced positive topline results from the phase 3 GLOW clinical trial evaluating the efficacy and safety of zolbetuximab in combination with CAPOX (a combination chemotherapy regimen that includes capecitabine and oxaliplatin). Zolbetuximab is an investigational first-in-class claudin-18.2 (CLDN18.2) targeted monoclonal antibody, for the first-line treatment of patients with CLDN18.2-positive, HER2-negative, locally […]

December 16, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 16 Dec 2022

HKUMed discovery may lead to therapeutic targets for cancer

Researchers from the Department of Clinical Oncology, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong (HKUMed) have discovered a novel subtype of Epstein-Barr Virus (EBV)-positive nasopharyngeal carcinoma (NPC) and EBV-associated immunosuppression in the tumor-microenvironment (TME). These findings have provided novel insights into the traditional NPC pathogenesis model and highlights EBV-specific […]

December 16, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 15 Dec 2022

Solve Therapeutics launches to tackle cancer

Solve Therapeutics, Inc. (SolveTx), an oncology-focused biopharmaceutical company, has launched with the mission of developing novel antibody-based therapies targeting tumor-specific antigens. The company’s formation reunites the former VelosBio Inc. team. SolveTx is fully operational with more than 25 employees and is actively pursuing discovery and development efforts at its 10,000-square-foot laboratory in San Diego. Solve […]

December 15, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 14 Dec 2022

STORM Therapeutics closes $30M Series B financing

STORM Therapeutics Ltd., which is working on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, has successfully completed a $30 million Series B financing round. The financing was co-led by existing investors M Ventures, Pfizer Ventures, Taiho Ventures LLC, Cambridge Innovation Capital (CIC) and new investors […]

December 14, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 14 Dec 2022

ImaginAb launches trial to study neoadjuvant immunotherapy

ImaginAb Inc., in collaboration with Memorial Sloan Kettering Cancer Center (MSK) and Melanoma Research Alliance (MRA), has launched an investigator-initiated phase II trial. It will explore the efficacy and safety of neoadjuvant immune checkpoint inhibitor treatment of stage III surgically resectable melanoma through use of CD8 ImmunoPET. ImaginAb is a global biotechnology company focused on […]

December 14, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 14 Dec 2022

Etcembly reveals breakthrough in optimizing TCR assets

Etcembly has announced the successful prediction and optimization of multiple T cell receptor (TCR) assets for targeting leukemias and solid tumors. The company’s machine learning platform EMLy (Etcembly machine learning) enables AI based engineering of novel TCRs from the complete theoretical TCR repertoire. The unification of machine-learning-based optimization with empirical validation has facilitated the rapid […]

December 14, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 14 Dec 2022

Asieris doses first patient in bladder cancer diagnostic trial

Asieris Pharmaceuticals has announced that Hexvix, a drug used for bladder cancer diagnosis, completed dosing for the first patient in its real-world clinical study at Hainan General Hospital Lecheng Branch. Hexvix has been approved in the U.S. and many European countries. The combined use of Hexvix and blue light cystoscopy (BLC) for the management of […]

December 14, 2022 - 2 minutesmins - By Jim Cornall

cancer protein degradation sibylla biotech

Interview 14 Dec 2022

Sibylla Biotech: how physicists met biologists to discover new drugs

Discovering new drugs remains an inefficient, trial and error-based process. The founding team behind the Italian startup Sibylla Biotech explain how their interdisciplinary approach can speed up drug discovery in the protein degradation space. Protein degradation is a hot field in the biotech industry, with many pharmaceutical companies forging lucrative deals with protein degradation players. […]

December 14, 2022 - 9 minutesmins - By Jonathan Smith

News and Trends 14 Dec 2022

OncoHost to launch PROphet for non-small cell lung cancer in the U.S. in 2023

Ofer Sharon is the CEO of OncoHost, a biotech company in the precision oncology space. A physician by training, Sharon has leveraged his experience in pharma drug development and entrepreneurship to lead OncoHost through the development of PROphet, the company’s host response profiling platform, which will launch in the U.S. for non-small cell lung cancer […]

December 14, 2022 - 7 minutesmins - By Jim Cornall

Knowledge hub

Categories

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Approaches

Therapeutic areas

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

Sanofi and Innate Pharma expand natural killer cell deal

LIfT BioSciences gets a double boost

Nykode Therapeutics and Richter-Helm BioLogics announce partnership

Astellas gastric cancer drug meets phase 3 primary endpoint

HKUMed discovery may lead to therapeutic targets for cancer

Solve Therapeutics launches to tackle cancer

STORM Therapeutics closes $30M Series B financing

ImaginAb launches trial to study neoadjuvant immunotherapy

Etcembly reveals breakthrough in optimizing TCR assets

Asieris doses first patient in bladder cancer diagnostic trial

Sibylla Biotech: how physicists met biologists to discover new drugs

OncoHost to launch PROphet for non-small cell lung cancer in the U.S. in 2023

Subscribe to our newsletter to get the latest biotech news!

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!